Tibco Introduces Spotfire Clinical to Improve Clinical Trials and Accelerate Drug Development
TIBCO Software Inc. announced the launch of TIBCO Spotfire® Clinical, providing an in-memory, analytics platform on the market that aims to allow clinical development teams to make faster and more accurate decisions. Through visual and interactive exploration of clinical data, Spotfire Clinical® will enable actionable decisions that enhance patient safety, streamline operations and accelerate time to market for new medications and devices.
Clinical development teams can visualize and interact with operational, clinical and safety data in a single interface to support forward-looking decisions. By leveraging the new integrated S+/R statistics and predictive analytics capabilities of the TIBCO Spotfire® Analytics Platform, users will be able to conduct advanced what-if scenarios and analysis to gain insights into data, without the intervention of IT resources or biostatisticians.
“We use TIBCO Spotfire software for analyzing and reviewing operational and medical data on all our clinical trials,” said John Keilty vice president of IT and Informatics, Infinity Pharmaceuticals. “With Spotfire, all our clinical, safety and operational data are available in real time. This enables us to shorten the time between critical development gates, and to meet key milestones sooner while simultaneously managing safety risk.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
